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Erythrocyte Long-Chain Omega-3 Fatty Acid Levels are Inversely Associated with
Mortality and with Incident Cardiovascular Disease: The Framingham Heart Study
Abstract
Background: The extent to which omega-3 fatty acid status is related to risk for death from any cause and
for incident cardiovascular disease (CVD) remains controversial. Objective: To examine these
associations in the Framingham Heart Study. Design: Prospective and observational. Setting:
Framingham Heart Study Offspring cohort. Measurements: The exposure marker was red blood cell levels
of eicosapentaenoic and docosahexaenoic acids (the Omega-3 Index) measured at baseline. Outcomes
included mortality (total, CVD, cancer, and other) and total CVD events in participants free of CVD at
baseline. Follow-up was for a median of 7.3 years. Cox proportional hazards models were adjusted for 18
variables (demographic, clinical status, therapeutic, and CVD risk factors). Results: Among the 2500
participants (mean age 66 years, 54% women), there were 350 deaths (58 from CVD, 146 from cancer,
128 from other known causes, and 18 from unknown causes). There were 245 CVD events. In
multivariable-adjusted analyses, a higher Omega-3 Index was associated with significantly lower risks (Pvalues for trends across quintiles) for total mortality (P = .02), for non-CVD and non-cancer mortality (P =
.009), and for total CVD events (P = .008). Those in the highest (>6.8%) compared to those in the lowest
Omega-3 Index quintiles (<4.2%) had a 34% lower risk for death from any cause and 39% lower risk for
incident CVD. These associations were generally stronger for docosahexaenoic acid than for
eicosapentaenoic acid. When total cholesterol was compared with the Omega-3 Index in the same
models, the latter was significantly related with these outcomes, but the former was not. Limitations:
Relatively short follow-up time and one-time exposure assessment. Conclusions: A higher Omega-3 Index
was associated with reduced risk of both CVD and all-cause mortality.
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Abstract
BACKGROUND: The extent to which omega-3 fatty acid status is related to risk for death from
any cause and for incident cardiovascular disease (CVD) remains controversial.
OBJECTIVE: To examine these associations in the Framingham Heart Study.
DESIGN: Prospective and observational.
SETTING: Framingham Heart Study Offspring cohort.

Author Manuscript

MEASUREMENTS: The exposure marker was red blood cell levels of eicosapentaenoic and
docosahexaenoic acids (the Omega-3 Index) measured at baseline. Outcomes included mortality
(total, CVD, cancer, and other) and total CVD events in participants free of CVD at baseline.
Follow-up was for a median of 7.3 years. Cox proportional hazards models were adjusted for 18
variables (demographic, clinical status, therapeutic, and CVD risk factors).
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RESULTS: Among the 2500 participants (mean age 66 years, 54% women), there were 350
deaths (58 from CVD, 146 from cancer, 128 from other known causes, and 18 from unknown
causes). There were 245 CVD events. In multivariable-adjusted analyses, a higher Omega-3 Index
was associated with significantly lower risks (P-values for trends across quintiles) for total
mortality (P = .02), for non-CVD and non-cancer mortality (P = .009), and for total CVD events (P
= .008). Those in the highest (>6.8%) compared to those in the lowest Omega-3 Index quintiles
(<4.2%) had a 34% lower risk for death from any cause and 39% lower risk for incident CVD.
These associations were generally stronger for docosahexaenoic acid than for eicosapentaenoic
acid. When total cholesterol was compared with the Omega-3 Index in the same models, the latter
was significantly related with these outcomes, but the former was not.
LIMITATIONS: Relatively short follow-up time and one-time exposure assessment.

Author Manuscript

CONCLUSIONS: A higher Omega-3 Index was associated with reduced risk of both CVD and
allcause mortality.
Keywords
Epidemiology; Prospective cohort study; Eicosapentaenoic acid; Docosahexaenoic acid; Omega-3
fatty acids

Introduction

Author Manuscript

Several recent studies have linked higher blood levels and/or dietary intakes of the longchain n-3 polyunsaturated fatty acids (PUFAs) with greater longevity. Plasma phospholipid
n-3 PUFA levels were inversely associated with total mortality rates in the Cardiovascular
Health Study,1 and similar associations were seen for this endpoint with the red blood cell
(RBC) content of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in the
Heart and Soul Study.2 This latter metric, called for simplicity the Omega-3 Index, has been
proposed as a risk factor for death from cardiovascular disease (CVD).3,4 Consistent with
these observations, there is an inverse relationship between the Omega-3 Index and the rate
of telomere attrition, a marker of cellular aging.5 Although early randomized controlled
trials with n-3 PUFAs found reduced overall mortality,6,7 other more recent studies8–11 have
not confirmed such a protective effect. Some of the potential reasons why recent studies may
have yielded null results for intervention with n-3 PUFAs (background use of statins,12 short
follow-up periods, low n-3 PUFA doses, improvements in acute care, etc.) have been
reviewed.13,14 In the present investigation, we examined the relations between RBC n-3
PUFA levels in participants in the Framingham Heart Study’s (FHS’s) Offspring cohort and
total mortality as the primary endpoint, with secondary endpoints of death from CVD and
other causes, and of incident coronary heart disease (CHD), CVD, and ischemic stroke.

Author Manuscript

Methods
The FHS is a longitudinal community-based cohort study that was initiated in 1948. Adult
children of the original cohort were recruited in 1971 into the Framingham Offspring
Cohort. The selection criteria for this cohort (and for the more racially diverse Framingham
Omni Cohort) have previously been described.15,16 We evaluated Framingham Offspring/
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Omni participants (n = 3021) who attended their 8th/3rd examination cycles (2005–2008).
Participants were excluded in hierarchical order if they were missing RBC FA measurements
or relevant clinical covariates (n = 122), leaving 2899. We also excluded 399 with a history
of CVD (ie, nonfatal CHD or stroke), leaving 2500 for the present investigation. The study
protocol was approved by the Institutional Review Board of the Boston University Medical
Center. Informed consent was provided by all participants.

Covariates and mortality outcomes

Author Manuscript

We considered 18 primary baseline demographic and CV risk covariates: sex, age, body
mass index, marital status, education level, employment status, health insurance status,
regular aspirin user, prevalent hypertensive status, use of cholesterol-lowering drugs,
prevalent diabetes, history of CVD, alcohol consumption, smoking status, physical activity
(in metabolic equivalent units), the total cholesterol to high-density lipoprotein cholesterol
ratio, systolic blood pressure, and C-reactive protein. Four mortality endpoints were
examined: total, CVD [fatal myocardial infarction (MI), CHD death, sudden cardiac death,
fatal ischemic stroke, or other CVD death), cancer, and other (ie, non-CVD, non-cancer;
Note that in the Framingham Heart Study, “other” causes of death were not specifically
identified]. Incident CVD-related endpoints were also examined: total CVD (total stroke,
total CHD, or CVD mortality), total stroke (any fatal or nonfatal ischemic stroke), and total
CHD (fatal or nonfatal MI, CHD death or sudden cardiac death).

RBC FA analysis

Author Manuscript

Blood was drawn after a 10- to 12-hour fast into an EDTA tube, and RBCs were separated
from plasma by centrifugation. The RBC fraction was frozen at −80°C immediately after
collection. RBC FA composition was determined as described previously.17 Briefly, RBCs
were incubated at 100°C using boron trifluoride methanol and hexane to generate FA methyl
esters that were then analyzed by gas chromatography with flame ionization detection. N-3
FAs analyzed included α-linolenic acid (ALA; 18:3n3), EPA (20:5n3), docosapentaenoic
acid (DPA; 22:5n3), DHA (22:6n3), and the Omega-3 Index (EPA + DHA).3 The
coefficients of variation for these were 10.7%, 7.8%, 3.8%, 3.3%, and 2.4%, respectively.

Statistical analysis

Author Manuscript

Sample characteristics were summarized using standard statistical metrics (eg, means,
standard deviations (SDs), and correlations). Hazard ratios were estimated using the survival
package in R.18 Primary analyses related incident clinical outcomes by date of event (or
censoring) to quintiles of the Omega-3 Index, with follow-up analyses adjusting for
demographic and medical history covariates. Secondary analyses explored relationships of
outcomes by quintiles of individual n-3 PUFA levels, of a modified Omega-3 Index that
included DPA, and by risk category of the Omega-3 Index (high risk, ≤4%; intermediate
risk, >4% to <8%; and low risk, ≥8%).19 In other analyses, we included the n-6 FAs as
covariates and also compared the n-6:n-3 ratio with the Omega-3 Index. Finally, baseline
total cholesterol levels were compared with the Omega-3 Index in the same models to get a
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sense of how this emerging risk factor compared with an established one. All analyses used
2-sided tests at the P < .05 statistical significance level.

Results
Cohort description

Author Manuscript

This analysis was performed on 2500 Framingham Offspring study participants who were
free of CVD at baseline and for whom FAs, clinical outcomes, and demographic covariates
were available. Follow-up ended on December 31, 2016 (maximum, 11.2 years; median, 7.3
years). Table 1 provides the baseline characteristics of the cohort by mortality status. The
average age was 66 years, and there were more women (57%) than men (43%). There were
350 deaths during the follow-up period: 58 were attributable to CVD (17%), 146 to cancer
(42%), 128 to other known causes (37%), and 18 from unknown causes (5%). Overall, there
were 245 incident cases of CVD, 119 of CHD, and 105 ischemic strokes. (Case and control
numbers and length of follow-up for each outcome are in Table S1).
The Omega-3 Index and total and cause-specific mortality

Author Manuscript

We estimated the associations between adjusted risk for fatal outcomes across quintiles of
the Omega-3 Index (Fig. 1, with details in Table S2). In the multivariable-adjusted model,
death from any cause was significantly and inversely associated with the Omega-3 Index (P
for trend = .02). When comparing individuals in the lowest quintile of the Omega-3 Index
(<4.2%) to those in the highest (>6.8%), risk was 34% lower. Median values for the extreme
quintiles were 3.7% and 7.8%. The modified Omega-3 Index (which included DPA)
performed no differently from the original metric (Table S3), and an examination of the
relations between risk and the three Omega-3 Index risk categories found a significant trend
across the categories (P = .04), but only the intermediate category differed significantly from
the high-risk category (possibly because there were 10-fold more subjects in the
intermediate than the highest categories; Table S4). When we controlled for RBC n-6 PUFA
levels in the original analysis, or substituted the n-6:n-3 ratio for the Omega-3 Index, there
was no material improvement in mortality hazard ratios (Table S5). In neither case did the
n-6 PUFAs alter the n-3 PUFA associations.

Author Manuscript

Regarding cause-specific mortality, the Omega-3 Index was only significantly associated
with risk for death from “other” (non-CVD, non-cancer) causes (P for trend = .009), with the
participants in the first (reference) quintile being at significantly higher risk than those in
quintiles 2–5. There was a trend for reduced risk for CVD across Omega-3 Index levels (eg,
there was a 61% lower risk between extreme quintiles), but with wide confidence intervals,
the differences were nonsignificant. The results for total and cause-specific mortality were
similar in analyses including all 2899 participants (ie, including those with a history of
CVD; Table S6).
The Omega-3 Index and CVD outcomes
The Omega-3 Index was significantly and inversely associated with total CVD, total CHD,
and total stroke after adjusting for covariates in a linear trend analysis across quintiles (Table
2; P values for trends = .008, .03, and .006, respectively). Unadjusted hazard ratios are
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shown in Table S7. The hazard ratio for total CVD was significantly reduced in quintile 5 vs
1, but for total CHD or total stroke, no individual quintile differed significantly from the
reference. Similar findings were observed in the full cohort (n = 2899) for total CHD and
total stroke, but the relationship with total CVD was no longer statistically significant (Table
S8). Using the modified Omega-3 Index (with DPA) did not change the pattern of results
(Table S3), and when Omega-3 risk categories were tested, the general pattern of
relationships remained the same, but they were mostly nonsignificant (Table S4). Finally,
neither including n-6 PUFAs as covariates nor replacing the Omega-3 Index with the n-6:n-3
ratio altered the original results (Table S5).
Individual RBC n-3 PUFAs and outcomes

Author Manuscript

The adjusted risk for experiencing the endpoints of interest by each of the four n-3 PUFAs
separately is shown in Table 3 (unadjusted hazard ratios in Table S9). The plant-derived n-3
PUFA, ALA, was not significantly associated with reduced risk for any of the outcomes
tested (Table 3). In general, as the levels of the EPA and (especially) DHA increased, risk for
disease outcomes and total (and other) mortality decreased (Table 3). The only outcome that
DPA was (marginally, P = .059) associated with was death from other causes (Table 3).
Omega-3 Index vs total cholesterol
In the head-to-head comparison of the Omega-3 Index and total cholesterol for total and
CVD mortality and for the 3 CVD outcomes, the former metric was significantly associated
with risk for 4 of the 5 outcomes, whereas the total cholesterol level, in the same models,
was not associated with risk for any of these outcomes (Table 4).
Discussion

Author Manuscript

In this study of participants in the Framingham Offspring study, the baseline Omega-3 Index
at about 66 years of age was inversely associated with total mortality over the next 7 years—
with values of the Omega-3 Index significantly lower in those who died during follow-up
than those who did not. The same was generally true for the 2 components of the Index, EPA
and DHA, but not for RBC DPA n-3 or ALA. Findings for the Omega-3 Index persisted in a
model adjusted for 18 other relevant variables including plasma lipids and C-reactive
protein.

Author Manuscript

We recently reported similar findings to these in the Women’s Health Initiative Memory
Study where there was a significant inverse trend across quartiles of the Omega-3 Index for
total mortality, with the highest quartile being at 22% lower risk for death compared with the
lowest.20 That study followed a nationwide sample of 6500, approximately 70-year-old
women for 15 years. Kleber et al. also found a 9% decrease in risk for all-cause mortality
per 1 SD increase in the Omega-3 Index after 10 years of follow-up in 3259 German CHD
patients.21 In the present study, we followed up 2500 men and women for half as long and
found an interquintile risk reduction of 34%. We also found reduced risk for total CVD
events, CHD events, and stroke. The approximately 50% lower risk for CVD mortality was,
however, not statistically significant, most likely due to having only 58 events in the analysis
(see below). Nevertheless, these findings are generally consistent with those of several metaanalyses that all linked higher n-3 PUFA biomarker levels with reduced risk for “coronary
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events”22 or fatal CHD.19,23 This study was somewhat unique, however, in exploring
relations between RBC n-3 PUFA levels instead of whole plasma or plasma phospholipid
n-3 PUFAs. But since these markers of n-3 PUFA status are strongly intercorrelated,24 this
coherence is expected.

Author Manuscript

The causes of death most strongly associated with the Omega-3 Index were non-CVD and
non-cancer, ie, “other” causes. By design, the FHS focused primarily on CVD outcomes, so
details of the other causes of death are unavailable. An 11% reduction (per 1 SD increase in
the Omega-3 Index) in risk for death from other causes was also seen in the women’s study
mentioned previously.20 It is unclear what mechanism might explain this observation; but
since n-3 PUFAs are known to have a wide variety of effects on cell membrane biology,25,26
a systemic impact of higher levels of these FAs on overall cellular health is possible. As
noted earlier, several recent randomized trials of fish oil with total mortality as an endpoint
have been null, but they typically showed trends toward a benefit.27,28 More consistent with
our observations was a 2017 meta-analysis,29 which found a significant 19% reduction in
risk for coronary death associated with fish oil treatment. Two nonrandomized retrospective
studies using governmental databases to track patient outcomes (one from England30 and
another from Italy31) reported lower risk for all-cause mortality in those CHD patients who
had been prescribed 1 g of fish oil at discharge. Finally, higher plasma long-chain n-3 FA
levels were strongly associated with reduced risk for total mortality and CHD outcomes in
renal transplant patients in Norway.32

Author Manuscript

A somewhat surprising observation in this study was the low rate of CVD in this population,
with only 17% of deaths being attributable to CVD (as opposed to 42% from cancer). Part of
this is clearly the exclusion from the analysis set of participants with CVD at baseline, but
even including these individuals, the CVD death rate was only 22%. This relatively low
CVD death rate should perhaps not be surprising given the reduction in heart disease
mortality in the United States over the last several decades. For example, the agestandardized death rate from heart disease per 100,000 people dropped from 520 in 1969 to
167 in 2014, a 68% decline.33

Author Manuscript

With regard to the individual RBC n-3 PUFAs studied here, in the multivariable-adjusted
model, ALA was not significantly related to any measured outcome in the quintile analysis.
The null mortality findings for ALA agree with some previous studies,34,35 but higher
circulating ALA levels (primarily plasma and plasma phospholipids) have been favorably
associated with CVD death,23 and ALA intake was associated with reduced total mortality
in a large randomized clinical trial (RCT) from Spain.36 So, evidence for ALA remains
mixed. Turning to DPA, in the final model, it was not related with any examined outcome
(although trends were favorable). This contrasts with a previous meta-analysis in which this
FA (again, more often measured in whole plasma or plasma phospholipids) was inversely
associated with risk for CVD death.23 In light of this and other prior reports (eg, in heart
failure37), the utility of RBC DPA as a risk marker remains unclear. Nevertheless, because of
the growing evidence for a beneficial role of DPA,38 it is reasonable to ask why this FA is
not a component of the Omega-3 Index. Including it would be reasonable if adding it to EPA
and DHA improved the utility of the metric in risk assessment. In the present study, we
compared the original and the modified Omega-3 Index (Table S3) and found essentially the
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same associations with outcomes for both. This would be expected since the correlation
between these 2 predictor variables is 0.98. Hence, our findings provide no compelling
reason to alter the original definition/components of the Omega-3 Index.

Author Manuscript

We found that the risk of stroke was inversely associated with the Omega-3 Index, but not in
a linear manner, ie, hazard ratios were reduced only in the upper 2 quintiles; however, the
trend across quintiles was significant. Risk reduction was largely associated with DHA,
where risk was 59% lower in the fifth (vs the first) quintile (P < .05). An association
between serum long-chain n-3 PUFA levels and stroke risk has been reported previously in
cross-sectional studies.39,40 The impact of marine n-3 PUFA levels on ischemic stroke may
extend beyond the risk of incident event. Lower plasma proportions of EPA and DHA have
been shown to be independently associated with increased ischemic stroke severity and, for
DHA, poor functional outcomes at 90 days after stroke.41 In addition, a higher ratio of EPA
or DHA to arachidonic acid in serum was associated with lower likelihood of early
neurologic deterioration after ischemic stroke.42 A 2012 meta-analysis of 32 observational
cohorts and 13 n-3 RCTs reported inverse associations with stroke and fish intake, but no
significant relations with either circulating biomarkers or with supplementation,43 although a
2017 study of plasma phospholipid omega-3 FA and incident stroke from 3 cohorts found
inverse relations with DHA as we did here.44 A randomized, open-label study in patients
surviving myocardial infarction45 showed a reduction in risk of nonfatal stroke with n-3 FA
supplementation, and an open-label study in Japan demonstrated no effect on primary
prevention of stroke but a 20% relative reduction in recurrent total stroke with EPA
supplementation.46 However, some studies have found no relations between n-3 PUFA levels
and stroke,47,48 so the n-3 PUFA and stroke literature is mixed, and more studies are needed.

Author Manuscript
Author Manuscript

A variety of exploratory analyses were conducted here. Given the controversies regarding
the CVD effects of the n-6 PUFAs and the frequent use of the n-6:n-3 ratio, in one analysis
we controlled for RBC n-6 PUFA levels and in another we directly compared the ratio with
the Omega-3 Index. In neither case did the n-6 PUFAs add or detract from the omega-3
effect. Hence, this study found no support for using a combined metric with n-6 and n-3
PUFAs. Finally, we compared associations with disease outcomes for the Omega-3 Index
with that of total cholesterol, one of the most well-known CVD risk factors. This analysis
was undertaken to give some perspective of the relative sensitivity of these 2 biomarkers. In
head-to-head comparisons with the same multivariable models, a higher Omega-3 Index was
significantly associated with reduced risk for 4 of the 5 outcomes studies, but cholesterol
was unrelated to risk for any outcome. This may be because about 38% of participants were
on a cholesterol-lowering medication, and so cholesterol levels at baseline were
therapeutically reduced; because 399 subjects with a diagnosis of CVD at baseline were
excluded; or because those who were particularly susceptible to cholesterol-induced CHD
may have already died. There is indeed some controversy regarding the predictive power of
serum cholesterol in older individuals.49 Nevertheless, in the unique context of this study in
which we controlled for 17 other variables, cholesterol levels were unassociated with these
outcomes. Whatever the reasons, this observation supports the need for further research to
more clearly define the relative roles of traditional and emerging biomarkers in risk
stratification.
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The originally proposed (in 2004) clinical cut-points for the Omega-3 Index were <4% (high
risk) and >8% (low risk).3 Although these have recently been confirmed in a meta-analysis
including 10 cohorts and over 27,000 subjects,19 it was of interest to explore their utility in
the present study as well. We found a significant trend across risk categories for total
mortality and significant reductions in risk for the intermediate group compared with the
high group, but not for the >8% category. This may reflect a nonlinear relationship between
the Omega-3 Index and risk as has been suggested by others,25 or the fact that only 10% of
the sample was in the >08% category. Nevertheless, the hazard ratio of 0.69 for any death in
the >8% category is at least suggestive of lower risk.

Author Manuscript

As alluded to earlier, mechanisms that may explain the associations between higher RBC
n-3 PUFA and improved longevity and reduced CVD risk are not clearly understood, but
there are beneficial effects of these FAs on a variety of CV risk factors. These include
reductions in serum triglyceride levels,50 blood pressure,51 platelet aggregation,52 heart rate,
53 susceptibility to ventricular fibrillation (in some settings),54 inflammatory markers,55,56
and plaque vulnerability57,58 along with improvements in endothelial function.59 The
observation that blood EPA + DHA levels are independently associated with slower rates of
telomere shortening,5 a purported marker of “cellular aging,” is yet another favorable
biomarker relationship, but it is not a molecular mechanism.

Author Manuscript

From an observational study, we cannot conclude that raising the Omega-3 Index will have
heart benefits and/or prolong life. Nevertheless, it is instructive to consider how much more
EPA + DHA an individual might need to consume to move the median Omega-3 Index in
quintile 1 (3.7%) to that in quintile 5 (7.8%). Based on a recent dose-response study,60 one
can estimate that it would take about 1300 more mg of EPA + DHA per day to do this. This
amount of EPA + DHA could be obtained from a single serving (100 g) of farmed salmon61
daily. Alternatively, 4 standard fish oil pills per day would suffice. Several early omega-3
RCTs used 800–1000 mg/d and reported reduced total mortality,6,7,62 whereas other more
recent studies at the same dose have not.9,11,63 Several possible reasons for this discrepancy
have been proposed.64,65
Strengths and limitations

Author Manuscript

The strengths of our investigation include the relatively large sample size from a wellcharacterized community, the unambiguous nature of the primary endpoint, and the use of an
objective and standardized biomarker of PUFA exposure that has low biological variability.
66 Weaknesses include the assessment of PUFA exposure at only one point in time (which
cannot capture changes in PUFA status that may have occurred during follow-up) and the
largely Caucasian cohort (which precludes firm conclusions regarding other races). Also, the
relatively low event rates, especially for CVD death, limited our ability to detect associations
with this endpoint. Although clearly affected by omega-3 PUFA intake, other factors can
influence the Omega-3 Index such as smoking and body weight,67 both of which were
controlled for here. What we did not (and could not) control for is heritability, which we
showed previously to explain about 24% of the variability in this biomarker.67 In the same
vein, we did not include in our models the intake of key nutrients (kilocalories, saturated
FAs, salt, fiber, etc.), which might contribute to the relationships reported here. However, by
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controlling for some of the physiological/metabolic consequences of consuming diets of
poor quality (body weight, blood pressure, hyperlipidemia, and CRP levels), as well as for
socioeconomic variables (which themselves track with poor diets), it is unlikely that
including individual nutrients would have altered the outcome of the study. As always, the
presence of residual or unmeasured confounding also precludes inferences about causality.
For example, despite controlling for multiple lifestyle/health factors, higher omega-3 PUFA
levels may simply be a marker for a healthier overall diet and behaviors, which themselves,
independent of the omega-3 levels, may be cardioprotective.

Author Manuscript

In conclusion, we observed that higher RBC levels of n-3 PUFAs were associated with
greater longevity and reduced risk for several CVD-related endpoints in this communitybased sample. These findings, in the context of the totality of available evidence on this
topic, provide further support for a role for the use of the Omega-3 Index in risk
stratification algorithms.
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APPENDIX
Table S1

Distribution of outcomes (n = 2500)
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Number of people
with events (cases)

Number of people
without events
(controls)

Median
* follow-up
days

Maximum
follow-up
*
days

Total CVD

245

2255

2351

3833

Total CHD

119

2381

2342

3815

Ischemic stroke

105

2395

2342

3833

CVD mortality

58

2442

2673

3815

350

2150

2686

3815

†

Death from any cause

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

Days to event or days to censoring.

†

The causes of the 350 observed deaths, besides CVD, were 146 cancer (42%), 128 other (37%), and 18 unknown (5%).

Table S2

Risk of fatal events by Omega-3 Index (n = 2500)

Author Manuscript

Hazard ratios (95% CIs)
CVD mortality

Cancer mortality

Other mortality

Any mortality

<4.2% (n = 508)

1.0

1.0

1.0

1.0

4.2%–4.9% (n = 500)

0.97 (0.41, 2.30)

0.94 (0.58, 1.55)

0.59 (0.34, 1.02)

0.81 (0.59, 1.12)

4.9%–5.7% (n = 501)

0.96 (0.43, 2.16)

0.88 (0.50, 1.57)

0.63 (0.36, 1.09)

0.78 (0.56, 1.10)

Omega-3 Index–unadjusted
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Hazard ratios (95% CIs)
CVD mortality

Cancer mortality

Other mortality

5.7%–6.8% (n = 502)

1.10 (0.46, 2.62)

0.72 (0.42, 1.23)

0.67 (0.40, 1.11)

>6.8% (n = 489)

0.88 (0.39, 2.01)

1.19 (0.72, 1.97)

0.53 (0.31, 0.91)

P-value for linear trend
§

.86

.85

.07

<4.2% (n = 508)

1.0

1.0

1.0

4.2%–4.9% (n = 500)

0.57 (0.23, 1.40)

0.66 (0.38, 1.14)

0.54 (0.31, 0.94)

Any mortality
0.73 (0.53, 1.02)

*

0.81 (0.58, 1.12)
.16

Omega-3 Index–adjusted

1.0

4.9%–5.7% (n = 501)

0.54 (0.20, 1.47)

0.73 (0.42, 1.28)

0.38 (0.20, 0.73)

5.7%–6.8% (n = 502)

0.56 (0.22, 1.43)

0.60 (0.35, 1.03)

0.44 (0.25, 0.79)

>6.8% (n = 489)

0.39 (0.15, 1.02)

0.96 (0.56, 1.64)

0.44 (0.24, 0.79)

Author Manuscript

P-value for linear trend

.10

.88

.009

†

*
†
†
†

0.74 (0.53, 1.04)
0.67 (0.46, 0.96)
0.59 (0.41, 0.86)
0.66 (0.45, 0.96)
.02

*
†
*

*

CVD, cardiovascular disease; CI, confidence interval.

*

P < .05

†

P < .01

‡

P < .001.

All significant hazard ratios/P-values are shown in bold italics.
§
Adjusted for all variables in Table 1 except baseline CVD.

Table S3

Risk of events by Omega-3 Index modified to include
docosapentaenoic acid (n = 2500)
Hazard ratios (95% CIs

Author Manuscript

Total CVD

Total CHD

Total stroke

Any mortality

<4.2% (n = 508)

1.0

1.0

1.0

1.0

4.2%–4.9% (n = 500)

1.06 (0.69, 1.63)

1.05 (0.60, 1.83)

1.16 (0.60, 2.24)

0.74 (0.53, 1.04)

4.9%–5.7% (n = 501)

1.10 (0.72, 1.68)

0.81 (0.44, 1.48)

1.30 (0.68, 2.49)

0.67 (0.46, 0.96)

5.7%–6.8% (n = 502)

0.74 (0.47, 1.17)

0.63 (0.34, 1.20)

0.59 (0.28, 1.25)

0.59 (0.41, 0.86)

>6.8% (n = 489)

0.61 (0.37, 0.99)

0.58 (0.29, 1.18)

0.45 (0.20, 1.03)

0.66 (0.45, 0.96)

Omega-3 Index–adjusted

P-value for linear trend

.008

†

*

.03

*

.006

†

.02

*
†
*

*

Modified Omega-3 Index (+DPA)–
adjusted

Author Manuscript

<6.7% (n = 510)

1.0

1.0

1.0

1.0

6.7%–7.5% (n = 497)

1.01 (0.66, 1.54)

0.93 (0.54, 1.61)

1.04 (0.52, 2.07)

0.75 (0.53, 1.06)

7.5%–8.4% (n = 502)

0.83 (0.54, 1.27)

0.58 (0.32, 1.05)

1.09 (0.57, 2.08)

0.48 (0.40, 0.84)

8.4%–9.7% (n = 507)

0.69 (0.44, 1.08)

0.54 (0.29, 1.01)

0.65 (0.31, 1.35)

0.72 (0.50, 1.04)

>9.7% (n = 484)

0.64 (0.40, 1.03)

0.54 (0.27, 1.05)

0.51 (0.23, 1.14)

0.61 (0.41, 0.90)

P-value for linear trend

.012

*

.013

*

.024

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

P < .05

†

P < .01

‡

P < .001.
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Author Manuscript

Adjusted for all variables in Table 1.

Table S4

Risk of events by Omega-3 Index risk categories (n =
2500)
Hazard ratios (95% CIs)
Total CVD

Total CHD

Total stroke

Any mortality

<4% (n = 416)

1.0

1.0

1.0

1.0

4%–8% (n = 1876)

1.03 (0.72, 1.48)

0.94 (0.57, 1.54)

1.12 (0.64, 1.94)

0.73 (0.56, 0.96)

>8% (n = 208)

0.77 (0.43, 1.38)

0.73 (0.34, 1.58)

0.88 (0.33, 2.32)

0.85 (0.68, 1.07)

.45

.48

.93

.15

<4% (n = 416)

1.0

1.0

1.0

1.0

4%–8% (n = 1876)

0.88 (0.59, 1.32)

0.85 (0.49, 1.47)

0.91 (0.48, 1.71)

0.61 (0.45, 0.83)

>8% (n = 208)

0.68 (0.36, 1.27)

0.83 (0.35, 1.94)

0.50 (0.17, 1.52)

0.69 (0.43, 1.13)

P-value for linear trend

.59

.23

.21

.04

Omega-3 Index–unadjusted

Author Manuscript

P-value for linear trend
§
Omega-3 Index–adjusted

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

P < .05

†

P < .01

‡

P < .001.

All significant hazard ratios/P-values are shown in bold italics.
§
Adjusted for all variables in Table 1.

Author Manuscript
Author Manuscript
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*

*

†

Author Manuscript

Author Manuscript
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§

1.64 (1.06, 2.53)
1.61 (0.99, 2.62)

4.56–5.20

>5.20

1.0
1.03 (0.67, 1.57)
1.04 (0.67, 1.62)
0.65 (0.40, 1.08)
0.48 (0.26, 0.91)
.014

<4.2%

4.2%–4.9%

4.9%–5.7%

5.7%–6.8%

>6.8%

P-value from trend

Omega-3 Index + all n-6 fatty acids

.008

1.69 (1.10, 2.62)

3.99–4.56

P-value for trend

1.11 (0.70, 1.78)

3.32–3.99

†

1.0

<3.31

†

0.61 (0.37, 0.99)

>6.8%
.008

0.74 (0.47, 1.17)

5.7%–6.8%

P-value for trend
§
n6:n3 ratio

1.10 (0.72, 1.68)

1.06 (0.69, 1.63)

4.2%–4.9%

4.9%–5.7%

1.0

Total CVD

<4.2%

Omega-3 Index

§

*

*

*

*
*

.14

0.62 (0.26, 1.44)

0.65 (0.32, 1.34)

0.85 (0.45, 1.58)

1.04 (0.59, 1.83)

1.0

.014

*

1.88 (0.95, 3.74)

1.62 (0.86, 3.06)

1.26 (0.65, 2.46)

0.93 (0.33, 1.96)

1.0

.03

0.58 (0.29, 1.18)

0.63 (0.34, 1.20)

0.81 (0.44, 1.48)

1.05 (0.60, 1.83)

1.0

Total CHD

Hazard ratios (95% CIs)

P < .001.

Adjusted for all variables in Table 1 except baseline CVD.

§

All significant hazard ratios/P-values are shown in bold italics.

‡

P < .01

P < .05

†

†

.02

*

0.33 (0.10, 1.04)

0.50 (0.22, 1.15)

1.22 (0.60, 2.47)

1.15 (0.59, 2.24)

1.0

.012

*

2.02 (0.88, 4.65)

2.52 (1.15, 5.54)

3.08 (1.45, 6.54)

1.34 (0.56, 3.19)

1.0

.006

0.45 (0.20, 1.03)

0.59 (0.28, 1.25)

1.30 (0.68, 2.49)

1.16 (0.60, 2.24)

1.0

Total stroke

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

Author Manuscript
Table S5

*

†

.16

0.37 (0.10, 1.31)

0.52 (0.18, 1.46)

0.46 (0.16, 1.35)

0.52 (0.20, 1.38)

1.0

.14

2.46 (0.93, 6.51)

1.12 (0.45, 2.75)

1.41 (0.58, 3.46)

1.17 (0.45, 3.02)

1.0

.10

0.39 (0.15, 1.02)

0.56 (0.22, 1.43)

0.54 (0.20, 1.47)

0.57 (0.23, 1.40)

1.0

CVD mortality

.58

0.92 (0.41, 2.10)

0.55 (0.28, 1.10)

0.72 (0.39, 1.32)

0.66 (0.38, 1.14)

1.0

.68

1.12 (0.65, 1.93)

0.75 (0.42, 1.35)

0.83 (0.48, 1.42)

0.65 (0.37, 1.15)

1.0

.88

0.96 (0.56, 1.64)

0.60 (0.35, 1.03)

0.73 (0.42, 1.28)

0.66 (0.38, 1.14)

1.0

Cancer mortality

†

.006

†

0.32 (0.13, 0.78)

0.33 (0.16, 0.68)

0.32 (0.17, 0.62)

0.43 (0.23, 0.78)

1.0

.023

†

2.43 (1.36, 4.35)

1.12 (0.62, 2.00)

0.83 (0.43, 1.59)

1.20 (0.66, 2.20)

1.0

.009

0.44 (0.24, 0.79)

0.44 (0.25, 0.79)

0.38 (0.20, 0.73)

0.54 (0.31, 0.94)

1.0

Other mortality

*

†

‡

†

†

†

†

*

*

*

0.61 (0.36, 1.04)

0.52 (0.34, 0.80)

0.63 (0.43, 0.92)

.025

*

*

†

*

†

*

*
0.67 (0.47, 0.95)

1.0

.019

*

1.58 (1.08, 2.31)

1.11 (0.78, 1.59)

1.00 (0.69, 1.45)

0.98 (0.67, 1.41)

1.0

.02

0.66 (0.45, 0.96)

0.59 (0.41, 0.86)

0.67 (0.46, 0.96)

0.74 (0.53, 1.04)

1.0

Any Mortality

Author Manuscript

The Omega-3 Index vs the n-6:n-3 ratio and vs the Omega-3 Index adjusting for all n-6 fatty acids (n = 2500)
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Table S6

Risk of fatal events by Omega-3 Index (n = 2899)
Hazard ratios (95% CIs)
Cancer mortality

Other mortality

CVD mortality

Any mortality

<4.2% (n = 580)

1.0

1.0

1.0

1.0

4.2%–4.9% (n = 579)

0.88 (0.58, 1.33)

0.66 (0.41, 1.07)

0.84 (0.44, 1.61)

0.83 (0.63, 1.09)

4.9%–5.7% (n = 580)

0.86 (0.53, 1.38)

0.62 (0.39, 1.01)

0.93 (0.50, 1.73)

0.78 (0.58, 1.04)

5.7%–6.8% (n = 580)

0.61 (0.37, 1.00)

0.65 (0.41, 1.03)

1.06 (0.56, 2.00)

0.72 (0.54, 0.96)

>6.8% (n = 480)

0.97 (0.62, 1.51)

0.58 (0.37, 0.92)

0.92 (0.51, 1.68)

0.79 (0.60, 1.04)

.96

.05

Omega-3 Index–unadjusted

Author Manuscript

P-value for linear trend

*

*

.51

.046

<4.2% (n = 580)

1.0

1.0

1.0

1.0

4.2%–4.9% (n = 579)

0.70 (0.43, 1.12)

0.65 (0.41, 1.03)

0.57 (0.23, 1.42)

0.79 (0.59, 1.06)

0.90 (0.45, 1.76)

0.70 (0.52, 0.95)

0.88 (0.42, 1.85)

0.66 (0.49, 0.90)

0.74 (0.36, 1.50)

0.71 (0.52, 0.97)

*

Omega-3 Index–adjusted

4.9%–5.7% (n = 580)

0.75 (0.46, 1.21)

5.7%–6.8% (n = 580)

0.55 (0.33, 0.91)

>6.8% (n = 480)

0.87 (0.55, 1.39)

P-value for linear trend

.45

0.38 (0.22, 0.67)

*

0.52 (0.31, 0.87)
0.49 (0.29, 0.84)
.01

‡
*
†

*

.87

.02

*
†
*

*

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

P < .05

†

P < .01

‡

P < .001.

Author Manuscript

All significant hazard ratios/P-values are shown in bold italics.
Adjusted for all variables in Table 1 except baseline CVD.

Table S7

Unadjusted risk of events by Omega-3 Index (n = 2500)
Hazard ratios (95% CIs)
Total CVD

Total CHD

Total stroke

<4.2% (n = 508)

1.0

1.0

1.0

4.2%–4.9% (n = 500)

1.08 (0.72, 1.63)

1.07 (0.63, 1.82)

1.19 (0.65, 2.20)

4.9%–5.7% (n = 501)

1.33 (0.90, 1.96)

0.88 (0.50, 1.53)

1.64 (0.92, 2.93)

5.7%–6.8% (n = 502)

0.88 (0.57, 1.34)

0.73 (0.41, 1.33)

0.77 (0.39, 1.53)

>6.8% (n = 489)

0.70 (0.45, 1.10)

0.59 (0.32, 1.07)

0.68 (0.32, 1.45)

Omega-3 Index–unadjusted

Author Manuscript

P-value for linear trend

.07

.03

*

.16

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

P < .05

†

P < .01

‡

P < .001.

All significant hazard ratios/P-values are shown in bold italics.
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Table S8

Risk of CVD-related events by Omega-3 Index (n =
2899)
Hazard ratios (95% CIs)
Total CVD

Total CHD

Total stroke

<4.2% (n = 580)

1.0

1.0

1.0

4.2%–4.9% (n = 579)

1.07 (0.76, 1.52)

0.81 (0.51, 1.28)

1.53 (0.88, 2.66)

4.9%–5.7% (n = 580)

1.24 (0.89, 1.73)

0.74 (0.47, 1.18)

1.77 (1.03, 3.02)

5.7%–6.8% (n = 580)

0.99 (0.70, 1.41)

0.80 (0.51, 1.27)

1.20 (0.67, 2.14)

>6.8% (n = 580)

0.88 (0.62, 1.26)

0.65 (0.41, 1.04)

1.19 (0.65, 2.20)

.40

.10

.92

<4.2% (n = 580)

1.0

1.0

1.0

4.2%–4.9% (n = 579)

1.11 (0.74, 1.67)

1.08 (0.67, 1.74)

1.36 (0.77, 2.45)

4.9%–5.7% (n = 580)

1.31 (0.90, 1.93)

0.85 (0.50, 1.44)

1.20 (0.63, 2.28)

5.7%–6.8% (n = 580)

1.00 (0.68, 1.46)

0.73 (0.46, 1.17)

>6.8% (n = 580)

0.82 (0.54, 1.25)

0.56 (0.32, 0.99)

Omega-3 Index–unadjusted

Author Manuscript

P-value for linear trend
§
Omega-3 Index–adjusted

P-value for linear trend

.25

.01

*

ǁ

*

0.76 (0.41, 1.40)

*

0.51 (0.26, 1.02)
.003

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

P < .05

†

P < .01

‡

Author Manuscript

P < .001.

All significant hazard ratios/P-values are shown in bold it.
§
Adjusted for all variables in Table 1.
ǁ
The highest quintile of the Omega-3 Index had significantly lower risk for total stroke than the second quintile [0.32 (0.15,
†
†
0.68) ] and the third quintile [0.38 (0.19, 0.74) ] after adjusted for all variables in Table 1.

Author Manuscript
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Author Manuscript

Author Manuscript
0.92 (0.60, 1.43)
0.89 (0.57, 1.38)
1.26 (0.84, 1.90)
.26

4.9–5.7% (n = 506)

5.7–6.8% (n = 505)

>6.8% (n = 510)

P-value for linear trend

1.0
1.36 (0.91, 2.03)

0.85 (0.57, 1.28)
0.78 (0.50, 1.21)

0.68–0.92% (n = 508)

>0.92% (n = 493)
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1.24 (0.84, 1.84)
0.95 (0.63, 1.44)
0.99 (0.66, 1.49)
0.90 (0.58, 1.40)
.36

0.44–0.55% (n = 504)

0.55–0.68% (n = 520)

0.68–0.92% (n = 497)

>0.92% (n = 486)

P-value for linear trend

1.0
1.07 (0.72, 1.60)
1.23 (0.83, 1.82)
0.86 (0.56, 1.31)

<3.69% (n = 513)

3.69–4.36% (n = 498)

4.36–5.01% (n = 498)

5.01–5.96% (n = 504)

Docosahexaenoic acid

1.0

<0.44% (n = 493)

Docosapentaenoic acid

.048

1.07 (0.69, 1.64)

0.55–0.68% (n = 510)

P-value for linear trend

1.32 (0.90, 1.94)

0.44–0.55% (n = 495)

*

1.0

<0.44% (n = 494)

Eicosapentaenoic acid

*

Stroke

0.71 (0.40, 1.28)

0.81 (0.46, 1.43)

1.0 (0.59, 1.70)

1.0

.10

0.60 (0.33, 1.09)

0.81 (0.46, 1.44)

0.73 (0.41, 1.28)

0.88 (0.51, 1.51)

1.0

.005

†

0.57 (0.32, 1.00)

0.53 (0.29, 0.95)

0.62 (0.34, 1.12)

1.04 (0.62, 1.74)

1.0

.51

1.10 (0.61, 1.97)

0.73 (0.40, 1.36)

0.88 (0.48, 1.61)

1.33 (0.77, 2.32)

1.0

*

0.78 (0.39, 1.55)

1.53 (0.86, 2.75)

1.26 (0.68, 2.32)

1.0

.98

1.21 (0.56, 2.60)

1.48 (0.79, 2.78)

1.37 (0.71, 2.63)

2.10 (1.12, 3.96)

1.0

.84

1.08 (0.52, 2.23)

1.22 (0.64, 2.33)

1.71 (0.86, 3.38)

1.67 (0.91, 3.07)

1.0

.34

1.68 (0.88, 3.21)

1.24 (0.62, 2.47)

0.99 (0.48, 2.04)

1.69 (0.88, 3.26)

1.0

*

1.28 (0.53, 3.11)

1.05 (0.46, 2.38)

1.09 (0.45, 2.60)

1.0

.35

0.78 (0.32, 1.89)

0.59 (0.24, 1.44)

0.71 (0.33, 1.55)

0.90 (0.43, 1.88)

1.0

.45

0.72 (0.30, 1.74)

1.02 (0.47, 2.23)

0.70 (0.27, 1.81)

1.09 (0.52, 2.29)

1.0

.53

1.32 (0.52, 3.35)

1.99 (0.75, 5.27)

1.59 (0.49, 4.26)

1.81 (0.72, 4.56)

1.0

CVD

CHD

CVD

4.2–4.9% (n = 496)

<4.2% (n = 483)

α-linolenic acid

Mortality

Total Events

Hazard ratios (95% CIs)

0.88 (0.52, 1.48)

0.73 (0.41, 1.32)

0.98 (0.60, 1.61)

1.0

.43

1.33 (0.80, 2.20)

0.99 (0.59, 1.66)

0.65 (0.37, 1.15)

1.06 (0.62, 1.81)

1.0

.68

0.93 (0.56, 1.53)

0.65 (0.40, 1.06)

0.74 (0.44, 1.27)

0.64 (0.37, 1.10)

1.0

.52

0.95 (0.58, 1.57)

0.58 (0.32, 1.04)

0.99 (0.60, 1.62)

0.76 (0.46, 1.28)

1.0

Cancer

*

0.68 (0.41, 1.13)

0.53 (0.31, 0.93)

0.50 (0.28, 0.88)

1.0

.01

0.62 (0.34, 1.12)

0.73 (0.39, 1.35)

0.82 (0.46, 1.46)

1.36 (0.81, 2.28)

1.0

.009

†

0.62 (0.34, 1.12)

0.54 (0.30, 0.97)

0.91 (0.53, 1.56)

1.12 (0.66, 1.91)

1.0

.81

0.97 (0.57, 1.65)

0.78 (0.46, 1.34)

0.81 (0.48, 1.36)

0.52 (0.28, 0.97)

1.0

Other

Author Manuscript
Table S9

*

*

*

*

0.84 (0.60, 1.16)

0.69 (0.48, 0.97)

0.84 (0.61, 1.16)

1.0

.15

0.87 (0.62, 1.23)

0.83 (0.59, 1.18)

0.72 (0.51, 1.03)

1.06 (0.77, 1.46)

1.0

.02

0.77 (0.55, 1.08)

0.64 (0.46, 0.89)

0.74 (0.52, 1.05)

0.89 (0.63, 1.22)

1.0

.73

1.04 (0.75, 1.45)

0.84 (0.60, 1.19)

0.95 (0.68, 1.32)

0.77 (0.54, 1.09)

1.0

Total

*

†

Author Manuscript

Unadjusted risk of events and mortality by individual omega-3 fatty acids (n = 2500)
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Author Manuscript

Author Manuscript
.07

P-value for linear trend
.03

0.59 (0.33, 1.07)

CHD

.13

0.67 (0.31, 1.42)

Stroke

All significant hazard ratios/P-values are shown in bold italics.
*
P < .05
†
P < .01
‡
P < .001.

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

0.72 (0.46, 1.12)

CVD
>5.96% (n = 487)
.93

1.03 (0.46, 2.34)

CVD

Mortality

.77

1.16 (0.70, 1.92)

Cancer

Author Manuscript

Total Events

.25

0.70 (0.36, 0.99)

Other

*
.41

0.86 (0.62, 1.19)

Total

Author Manuscript

Hazard ratios (95% CIs)
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Figure 1.

Relations between quintiles of the Omega-3 Index and hazard ratios (+95% confidence
interval) for death from CVD (n = 58), cancer (n = 146), other causes (n = 128), and all
causes (n = 350, including 18 of unknown causes). Data are from 2500 participants free of
baseline CVD followed for a median of 7.3 years. Adjusted for all variables in Table 1. Pvalues for trend are shown above the columns. CVD, cardiovascular disease; CHD, coronary
heart disease.
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Table 1

Demographic overview (n = 2500)

Author Manuscript

Died (n = 350)
Variable

Still living (n = 2150)

Total

% (n) or mean (SD)

Sex
Male

52.9% (185)

41.5% (893)

43.1% (1078)

Female

47.1% (165)

58.5% (1257)

56.9% (1422)

Age

72.9 (8.6)

64.4 (8.2)

65.56 (8.76)

BMI

27.9 (5.9)

28.3 (5.4)

28.2 (5.4)

4.3% (15)

6.7% (144)

6.4% (159)

Married

63.7% (223)

70.7% (1519)

69.7% (1742)

Separated/divorced

12.0% (42)

12.7% (273)

12.6% (315)

Widowed

18.3% (64)

9.4% (203)

10.7% (267)

Marital status
Single/never married

Author Manuscript

Education
Some high school or less

6.0% (21)

2.4% (51)

2.9% (72)

High school graduate

33.7% (118)

24.8% (533)

26.0% (651)

Some college or vocational

22.9% (78)

21.9% (471)

22.0% (549)

College graduate

36.6% (128)

50.5% (1086)

48.6% (1214)

31.1% (109)

56.3% (1210)

52.8% (1319)

Employment
Employed
Disabled/unemployed
Retired

3.1% (11)

2.5% (53)

64.3% (225)

40.8% (877)

2.6% (64)
44.1% (1102)

Health insurance status

Author Manuscript

No insurance

2.3% (8)

1.9% (40)

1.9% (48)

Insurance, but no prescription

11.4% (40)

8.4% (181)

8.8% (221)

Full insurance

84.0% (294)

88.7% (1906)

88.0% (2200)

Regular aspirin use

49.7% (174)

38.6% (830)

40.2% (1004)

Prevalent hypertension

57.1% (200)

42.2% (908)

44.3% (1108)

Cholesterol medication

41.4% (145)

36.9% (794)

37.6% (939)

Prevalent diabetes

22.3% (78)

11.6% (249)

13.1% (327)

None

34.0% (119)

23.2% (499)

24.7% (618)

<1 drink per day

36.0% (126)

50.7% (1089)

48.6% (1215)

1–2 drinks per day

22.6% (79)

20.2% (434)

20.5% (513)

Alcohol consumption

>2 drinks per day

Author Manuscript

6.9% (24)

5.7% (123)

5.9% (147)

Not current smoker

89.1% (312)

90.5% (1946)

90.3% (2258)

Current

10.6% (37)

9.3% (200)

9.5% (237)

Smoking

METS

4.7 (15.4)

3.3 (8.6)

3.5 (9.9)

Total to HDL cholesterol ratio

3.5 (1.1)

3.5 (1.0)

3.5 (1.1)

133.6 (19.8)

128.2 (16.9)

129.0 (17.4)

Systolic BP
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Died (n = 350)

Author Manuscript

Variable
C-reactive protein

Still living (n = 2150)

Total

% (n) or mean (SD)
4.9 (12.7)

3.0 (6.1)

3.3 (7.4)

BMI, body mass index; METS, metabolic equivalents; HDL, high-density lipoprotein; BP, blood pressure.
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Table 2

Adjusted risk of events by Omega-3 Index (n = 2500)

§

Author Manuscript

Hazard ratios (95% CIs)
Total CVD

Total CHD

Total stroke

<4.2% (n = 508)

1.0

1.0

1.0

4.2%–4.9% (n = 500)

1.06 (0.69, 1.63)

1.05 (0.60, 1.83)

1.16 (0.60, 2.24)

4.9%–5.7% (n = 501)

1.10 (0.72, 1.68)

0.81 (0.44, 1.48)

1.30 (0.68, 2.49)

5.7%–6.8% (n = 502)

0.74 (0.47, 1.17)

0.63 (0.34, 1.20)

0.59 (0.28, 1.25)

>6.8% (n = 489)

0.61 (0.37, 0.99)

0.58 (0.29, 1.18)

0.45 (0.20, 1.03)

P-value for linear trend

.008

Omega-3 Index

†

*

.03

*

.006

†

Author Manuscript

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

P < .05

†

P < .01.

All significant hazard ratios/P-values are shown in bold italics.

§

Adjusted for all variables in Table 1 except baseline CVD.
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Author Manuscript
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Author Manuscript
0.98 (0.62, 1.56)
1.00 (0.63, 1.61)
1.16 (0.75, 1.80)
84

4.9%–5.7% (n = 506)

5.7%–6.8% (n = 505)

>6.8% (n = 510)

P-value for linear trend .

1.34 (0.90, 1.99)
1.20 (0.77, 1.87)
0.77 (0.49, 1.20)
0.87 (0.55, 1.39)
.11

0.44%–0.55% (n = 495)

0.55%–0.68% (n = 510)

0.68%–0.92% (n = 508)

>0.92% (n = 493)

P-value for linear trend
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1.17 (0.78, 1.77)
0.83 (0.55, 1.27)
0.87 (0.56, 1.36)
0.92 (0.58, 1.46)
.31

0.44%–0.55% (n = 504)

0.55%–0.68% (n = 520)

0.68%–0.92% (n = 497)

>0.92% (n = 486)

P-value for linear trend

1.0
0.98 (0.64, 1.50)

<3.69% (n = 513)

3.69%–4.36% (n = 498)

Docosahexaenoic acid

1.0

<0.44% (n = 493)

Docosapentaenoic acid

1.0

<0.44% (n = 494)

Eicosapentaenoic acid

1.45 (0.94, 2.22)

1.0

0.90 (0.51, 1.57)

1.0

.13

0.60 (0.31, 1.15)

0.83 (0.47, 1.48)

0.64 (0.36, 1.15)

0.86 (0.49, 1.51)

1.0

.02

*

0.69 (0.37, 1.29)

0.45 (0.24, 0.86)

0.74 (0.30, 1.38)

1.13 (0.66, 1.93)

1.0

.43

1.03 (0.55, 1.94)

0.78 (0.40, 1.53)

1.00 (0.52, 1.92)

1.44 (0.78, 2.65)

1.0

*

*

1.14 (0.60, 2.17)

1.0

.65

1.17 (0.52, 2.66)

1.22 (0.57, 2.63)

1.24 (0.60, 2.54)

2.09 (1.05, 4.16)

1.0

.57

0.95 (0.43, 2.11)

1.13 (0.54, 2.35)

1.78 (0.88, 3.60)

1.61 (0.83, 3.15)

1.0

.59

1.42 (0.69, 2.92)

1.27 (0.62, 2.64)

0.93 (0.43, 2.02)

1.59 (0.77, 3.25)

1.0

0.67 (0.26, 1.71)

1.0

.58

0.90 (0.34, 2.37)

0.40 (0.14, 1.14)

0.92 (0.37, 2.27)

0.64 (0.24, 1.70)

1.0

.36

0.58 (0.21, 1.61)

0.81 (0.32, 2.05)

0.64 (0.26, 1.62)

0.72 (0.30, 1.73)

1.0

.16

1.78 (0.62, 5.06)

3.06 (1.09, 8.60)

1.79 (0.59, 5.44)

1.76 (0.62, 4.93)

1.0

CVD

4.2%–4.9% (n = 496)

<4.2% (n = 483)

α-linolenic acid

Mortality
Stroke

CVD

CHD

Total Events

Hazard ratios (95% CIs)

*

0.70 (0.41, 1.19)

1.0

.87

1.15 (0.68, 1.94)

0.86 (0.49, 1.51)

†

†

0.43 (0.24, .0.78)

1.0

.059

0.60 (0.30, 1.17)

0.91 (0.45, 1.85)

0.89 (0.48, 1.67)
0.52 (0.27, 0.99)

*

1.0

.03

*

0.71 (0.39, 1.30)

0.41 (0.22, 0.79)

0.81 (0.47, 1.41)

0.98 (0.54, 1.77)

1.34 (0.76, 2.34)

*

*

1.0

.94

0.85 (0.48, 1.52)

0.84 (0.46, 1.54)

0.92 (0.49, 1.70)

0.51 (0.26, 1.02)

1.0

Other

1.02 (0.60, 1.73)

1.0

.63

0.83 (0.49, 1.41)

0.58 (0.35, 0.97)

0.69 (0.40, 1.19)

0.50 (0.27, 0.93)

1.0

.48

0.91 (0.54, 1.53)

0.54 (0.28, 1.03)

1.05 (0.65, 1.71)

0.71 (0.41, 1.21)

1.0

Cancer

§

Author Manuscript

Adjusted risk of events and mortality by individual omega-3 fatty acids (n = 2500)

0.78 (0.55, 1.11)

1.0

.10

0.81 (0.56, 1.17)

0.74 (0.51, 1.07)

0.71 (0.50, 1.01)

0.93 (0.66, 1.29)

1.0

.03

0.74 (0.52, 1.06)

0.58 (0.41, 0.84)

0.66 (0.47, 0.95)

0.78 (0.55, 1.10)

1.0

.64

1.04 (0.73, 1.47)

0.96 (0.67, 1.39)

1.04 (0.72, 1.50)

0.84 (0.58, 1.21)

1.0

Total

†

*

Author Manuscript
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Author Manuscript
.004

†

0.57 (0.35, 0.92)

*

Stroke

.03

0.54 (0.27, 1.07)

0.61 (0.32, 1.14)

.002

†

0.41 (0.18, 0.93)

0.57 (0.27, 1.20)

1.27 (0.68, 2.38)

Adjusted for all variables in Table 1 except history of CVD.

§

All significant hazard ratios/P-values are shown in bold italics.

P < .01.

P < .05

†

*

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

P-value for linear trend

>5.96% (n = 487)

0.71 (0.44, 1.12)

5.01%–5.96% (n = 504)

0.68 (0.37, 1.25)

*
.14

0.43 (0.17, 1.10)

0.76 (0.29, 1.97)

0.61 (0.22, 1.72)

CVD

0.99 (0.65, 1.50)

CVD
4.36%–5.01% (n = 498)

Mortality
CHD

Author Manuscript

Total Events

.98

0.92 (0.54, 1.56)

0.77 (0.45, 1.31)

0.62 (0.35, 1.11)

Cancer

.054

0.47 (0.27, 0.81)

0.47 (0.26, 0.87)

0.38 (0.20, 0.71)

Other

†

*

†

.06

0.68 (0.47, 0.99)

0.72 (0.50, 1.05)

0.61 (0.42, 0.88)

Total

Author Manuscript

Hazard ratios (95% CIs)

*

†
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Table 4

Author Manuscript

Omega-3 Index and total cholesterol: Associations with risk for disease outcomes (n =
2500)
Hazard ratios (95% CIs)
Biomarker

Total CVD

Total CHD

Total Stroke

CVD mortality

Any Mortality

<4.2% (n = 506)

1.0

1.0

1.0

1.0

1.0

4.2%–4.9% (n = 500)

1.08 (0.70, 1.65)

1.06 (0.61, 1.85)

1.20 (0.63, 2.27)

0.65 (0.27, 1.54)

0.74 (0.53, 1.03)

4.9%–5.7% (n = 500)

1.11 (0.73, 1.68)

0.81 (0.44, 1.47)

1.32 (0.69, 2.50)

0.53 (0.19, 1.49)

0.67 (0.47, 0.97)

5.7%–6.8% (n = 502)

0.74 (0.47, 1.17)

0.63 (0.34, 1.19)

0.61 (0.29, 1.27)

0.58 (0.22, 1.55)

>6.8% (n = 489)

0.63 (0.39, 1.01)

0.59 (0.30, 1.17)

0.47 (0.21, 1.06)

0.44 (0.16, 1.91)

§

Omega-3 Index

ǁ
P-value from linear trend test

.009

†

.03

*

.006

†

.19

0.58 (0.41, 0.84)

†

0.65 (0.45, 0.94)
.01

*

Author Manuscript

§

Total cholesterol

<154 (n = 406)

1.0

1.00

1.0

1.0

1.0

154–175 (n = 491)

1.03 (0.69, 1.56)

1.02 (0.55, 1.89)

0.88 (0.47, 1.66)

1.22 (0.53, 2.77)

0.73 (0.50, 1.05)

176–194 (n = 520)

0.95 (0.62, 1.45)

1.29 (0.71, 2.37)

0.63 (0.31, 1.27)

0.67 (0.26, 1.77)

0.72 (0.49, 1.06)

195–218 (n = 551)

0.89 (0.56, 1.39)

1.01 (0.53, 1.92)

0.69 (0.32, 1.40)

1.07 (0.30, 3.79)

0.91 (0.64, 1.31)

>218 (n = 530)

1.09 (0.66, 1.80)

1.59 (0.81, 3.11)

0.89 (0.41, 1.93)

0.31 (0.72, 1.34)

0.96 (0.66, 1.40)

ǁ
P-value from linear trend test

.99

.26

.50

.27

.11

CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.

*

P < .05

†

P < .01

Author Manuscript

All significant hazard ratios/P-values are shown in bold italics.

§

Hazard ratios presented here were adjusted for all variables in Table 1 with the addition of grouped total cholesterol (and removing total
cholesterol to high-density lipoprotein cholesterol ratio) and the grouped Omega-3 Index.

ǁ

§

Linear trend test models were fit for both the Omega-3 Index and TC simultaneously, after adjusting for variables as described in footnote “ ”.
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